165 related articles for article (PubMed ID: 27785922)
1. Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer.
Hu K; Zhang J; Yu M; Xiong C
Future Oncol; 2017 Mar; 13(6):489-498. PubMed ID: 27785922
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
3. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
[TBL] [Abstract][Full Text] [Related]
5. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.
Liu S; Zha J; Lei M
Clin Transl Oncol; 2018 Mar; 20(3):374-381. PubMed ID: 28766096
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting the MNK-eIF4E-β-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy.
Li Z; Sun Y; Qu M; Wan H; Cai F; Zhang P
Oncotarget; 2017 Jan; 8(2):2906-2915. PubMed ID: 27926520
[TBL] [Abstract][Full Text] [Related]
9. Induction of MNK Kinase-dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors.
Pham TND; Kumar K; DeCant BT; Shang M; Munshi SZ; Matsangou M; Ebine K; Munshi HG
Mol Cancer Ther; 2019 Feb; 18(2):235-244. PubMed ID: 30446586
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Grzmil M; Seebacher J; Hess D; Behe M; Schibli R; Moncayo G; Frank S; Hemmings BA
Cell Signal; 2016 Sep; 28(9):1412-1421. PubMed ID: 27289018
[TBL] [Abstract][Full Text] [Related]
11. First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.
Ramalingam S; Gediya L; Kwegyir-Afful AK; Ramamurthy VP; Purushottamachar P; Mbatia H; Njar VC
Oncotarget; 2014 Jan; 5(2):530-43. PubMed ID: 24504069
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
13. The MNK-1/eIF4E pathway as a new therapeutic pathway to target inflammation and remodelling in asthma.
Seidel P; Sun Q; Costa L; Lardinois D; Tamm M; Roth M
Cell Signal; 2016 Oct; 28(10):1555-62. PubMed ID: 27418099
[TBL] [Abstract][Full Text] [Related]
14. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
[TBL] [Abstract][Full Text] [Related]
15. eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma.
Liu T; Li R; Zhao H; Deng J; Long Y; Shuai MT; Li Q; Gu H; Chen YQ; Leng AM
Oncotarget; 2016 Oct; 7(41):66851-66864. PubMed ID: 27588477
[TBL] [Abstract][Full Text] [Related]
16. Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin.
Xu Y; Liao S; Wang L; Wang Y; Wei W; Su K; Tu Y; Zhu S
Cancer Chemother Pharmacol; 2021 Jan; 87(1):85-93. PubMed ID: 33159561
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting MNK Selectively Targets Cervical Cancer via Suppressing eIF4E-Mediated β-Catenin Activation.
Zhang W; Su X; Li S; Wang Y; Wang Q; Zeng H
Am J Med Sci; 2019 Sep; 358(3):227-234. PubMed ID: 31327462
[TBL] [Abstract][Full Text] [Related]
18. Inhibition MNK-eIF4E-β-catenin preferentially sensitizes gastric cancer to chemotherapy.
Yang X; Liu Z; Yin X; Zeng Y; Guo G
Fundam Clin Pharmacol; 2022 Aug; 36(4):712-720. PubMed ID: 35048413
[TBL] [Abstract][Full Text] [Related]
19. Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer.
Zhu Y; Wang C; Li M; Yang X
J Pharm Pharmacol; 2021 Sep; 73(10):1418-1426. PubMed ID: 34254647
[TBL] [Abstract][Full Text] [Related]
20. EGPI-1, a novel eIF4E/eIF4G interaction inhibitor, inhibits lung cancer cell growth and angiogenesis through Ras/MNK/ERK/eIF4E signaling pathway.
Qi X; Zhang S; Chen Z; Wang L; Zhu W; Yin C; Fan J; Wu X; Wang J; Guo C
Chem Biol Interact; 2022 Jan; 352():109773. PubMed ID: 34902296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
